# GenAssist

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genassist

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.genassisttx.com
- Total disclosed funding: $1.4M
- Latest round: Series A (Nov 18, 2022)
- Investors on record: 4

## About

Based in Suzhou, China and established in 2020, GenAssist operates as a biotechnology company that engages in research and development of gene editing drug. The founder of the company, He Chunyan, PhD in Immunology from Shanghai Jiaotong University, worked in Fosun Group, Tasly Group, Sunshine Insurance and other companies. The CSO of the company, Dr. Xing Chang, works as an associate professor at Westlake University.

The company specializes in the development of therapeutic drugs for neuromuscular diseases bases on TAM base editing technology platform. The company's first product is for Duchenne Muscular Dystrophy (DMD) series of gene mutation diseases. The company's product pipeline can be used to treat Duchenne muscular dystrophy.

## Funding rounds

- Series A, Nov 18, 2022, $1.4M — Hong Shan, Baidu Ventures, Astra Zeneca CICC Healthcare Venture Capital Fund
- Angel, Dec 22, 2020 — Redhill Capital

## Investors

- Redhill Capital (https://capitalatlas.ai/funds/redhill-capital) — Angel
- Hong Shan — Series A
- Baidu Ventures (https://capitalatlas.ai/funds/baidu-ventures) — Series A
- Astra Zeneca CICC Healthcare Venture Capital Fund — Series A